Closed-loop insulin delivery for treatment of type 1 diabetes
Замкнутая система доставки инсулина для лечения сахарного диабета 1 типа
2011-11-09
SCID: 54.1/yhshtdv5
Discuss with AI
artificial pancreasclosed-loop insulin deliverycontinuous glucose monitoringinsulin pumptype 1 diabetes
Figures from the paper
Abstract (AI)
Type 1 diabetes is one of the most common endocrine problems in childhood and adolescence, and remains a serious chronic disorder with increased morbidity and mortality, and reduced quality of life. Technological innovations positively affect the management of type 1 diabetes. Closed-loop insulin delivery (artificial pancreas) is a recent medical innovation, aiming to reduce the risk of hypoglycemia while achieving tight control of glucose. Characterized by real-time glucose-responsive insulin administration, closed-loop systems combine glucose-sensing and insulin-delivery components. In the most viable and researched configuration, a disposable sensor measures interstitial glucose levels, which are fed into a control algorithm controlling delivery of a rapid-acting insulin analog into the subcutaneous tissue by an insulin pump. Research progress builds on an increasing use of insulin pumps and availability of glucose monitors. We review the current status of insulin delivery, focusing on clinical evaluations of closed-loop systems. Future goals are outlined, and benefits and limitations of closed-loop therapy contrasted. The clinical utility of these systems is constrained by inaccuracies in glucose sensing, inter- and intra-patient variability, and delays due to absorption of insulin from the subcutaneous tissue, all of which are being gradually addressed.
Key Findings
1
Clinical progress has been enabled by wider insulin-pump use and increasing availability of continuous glucose-monitoring technologies.
2
Clinical utility remains limited by sensor inaccuracies, inter- and intra-patient variability, and delays in subcutaneous insulin absorption.
3
Closed-loop insulin delivery combines continuous interstitial glucose sensing with an algorithm-controlled insulin pump to provide real-time glucose-responsive therapy.
4
The artificial pancreas aims to reduce hypoglycemia risk while achieving tighter glucose control in people with type 1 diabetes.
5
These technical limitations are being progressively addressed, supporting further development of closed-loop therapy for type 1 diabetes.
Research Object
closed-loop insulin delivery systems (artificial pancreas) for type 1 diabetes
Research Subject
clinical effectiveness and limitations of real-time glucose-responsive insulin administration, particularly glycemic control and hypoglycemia risk
Publication Details
Publication Date
2011-11-09
Journal
Publisher
ISSN
Cited by
103
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai6
Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes2010
In Silico Preclinical Trials: A Proof of Concept in Closed-Loop Control of Type 1 Diabetes2009
Model Predictive Control of Type 1 Diabetes: An in Silico Trial2007
Simulation Environment to Evaluate Closed-Loop Insulin Delivery Systems in Type 1 Diabetes2010
Zone Model Predictive Control: A Strategy to Minimize Hyper- and Hypoglycemic Events2010
A Closed-Loop Artificial Pancreas Using Model Predictive Control and a Sliding Meal Size Estimator2009